Faridoxorubicin Program Clinical Updates
Avacta Group PLC has announced significant clinical updates for its faridoxorubicin program, removing the cardiac dosing limit and identifying a path for dose selection in future efficacy studies. This decision stems from highly favorable safety data, allowing patients to receive nearly four times the conventional doxorubicin dose and a maximum cumulative exposure of 550 mg/m² without severe cardiac toxicity. The company will now enroll final Phase 1b cohorts to compare two dose levels, aiming to determine the optimal biologic dose for upcoming efficacy trials, underscoring growing confidence in the tolerability of their pre|CISION® platform.
Select text to share a quote on X · sign in to keep highlights & notes in your AVCT notes
| LONDON and PHILADELPHIA - February 3, 2026 - Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre | CISION®, a tumor-activated oncology delivery platform, has published two key clinical updates to its faridoxorubicin (AVA6000) clinical program. |
Agreed updates to the trial protocol include the removal of the maximum dosing limit and to allow flexibility in dosing levels. These two developments underscore the growing confidence from investigators and regulators in the tolerability profile of faridoxorubicin and should support a smooth transition to future efficacy studies.
The historic maximum dosing limit which is based on the patient's exposure to released (free) doxorubicin, has been removed in the clinical trial following the collection of highly favorable safety data from the faridoxorubicin program and observation of patients receiving the highest cumulative doses for prolonged periods. Dosing in the Phase 1 clinical trial escalated to a dose of nearly 4x the conventional dose of doxorubicin and the maximum cumulative exposure of released doxorubicin was increased to 550 mg/m2 during the trial with no severe cardiac toxicity observed.
| One of the key advantages of the pre | CISION® platform is that its unique delivery mechanism allows patients to receive the drug for longer and at higher doses due to improved tolerability, with the potential to extend the progression free survival endpoint in trials. |
The Company's second significant update relates to the determination of the dose for the study in efficacy trials. The final cohorts of patients with the selected indications in Phase 1b will be enrolled, enabling two dose levels to be compared in order to determine the optimal biologic dose in future trials.
Updates to the clinical program will appear in the National Library of Medicine's clinicaltrials.gov entry for Faridoxorubicin (AVA6000) under the trial designation, ID Number NCT04969835.
Christina Coughlin, CEO of Avacta Therapeutics commented,
| "These two critical steps in the development of our faridoxorubicin (AVA6000) program and by extension the proprietary pre | CISION® platform demonstrate growing recognition by regulators of the safety of this platform. |
"Highly favorable cardiac safety data for faridoxorubicin enable patients to be treated longer, as opposed to stopping the drug for a theoretical risk of cardiac toxicity which is the usual practice with doxorubicin therapy. Despite dosing to nearly 4x the standard dose of doxorubicin as well as to a higher lifetime maximum exposure, we have not seen a single case of severe cardiac toxicity.
| Furthermore, identifying the path forward to the selection of the optimal biologic dose will enable a smooth transition to efficacy studies with faridoxorubicin program and allows the Company to implement these approaches in the platform currently in Phase 1b, facilitating the development across pre | CISION® medicines." |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.